Mundipharma International Corp. Ltd. has acquired from Germany-based CellAct Pharma GMBH worldwide development, commercialization and manufacturing rights to "smart" chemotherapy agent CAP7-1 – a Phase II compound it hopes to progress in biliary tract cancer, a disease with limited treatment options.
CAP7-1, a novel pro-drug of anticancer agent etoposide invented at Charité-Universitätsmedizin Berlin, has been has been moved by CellAct into Phase II with only €10m in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?